HASELMEIER has been 100% owned by SULZER since October 2020.

At what enterprise value was HASELMEIER acquired in 2020?

During the acquisition of HASELMEIER by SULZER in 2020, the transaction's Enterprise Value is estimated to be in the range of 100M - 350M EUR.

What was the EV/EBITDA of HASELMEIER when it was acquired by SULZER?

The estimated EV/EBITDA multiple for HASELMEIER is in the range of 15x - 25x.

When was HASELMEIER acquired by SULZER?

HASELMEIER was acquired by SULZER in 2020.

What was the revenue of HASELMEIER at the time of the deal?

The revenue of HASELMEIER at the time of the deal is estimated to be in the range of 25M - 50M EUR.

What was the EBITDA of HASELMEIER during the acquisition?

HASELMEIER's EBITDA is estimated to be in the range of 5M - 25M EUR.

How is the data for the HASELMEIER acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the HASELMEIER deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.sulzer.com/en/-/media/files/news/2020/200824_sulzer_to_acquire_haselmeier.pdf

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaHASELMEIER

10/2020

HASELMEIER acquired by SULZER

SWITZERLAND Life Sciences / Medical Devices / Medical Consumables EV 100M - 350M EUR

Context

Sulzer has completed the acquisition of Haselmeier, integrating the drug delivery specialist into its Applicator Systems (APS) division. The transaction was structured to acquire 100% of the privately held Swiss-German company, allowing Sulzer to immediately scale its healthcare business and leverage Haselmeier’s significant portfolio of proprietary intellectual property.The strategic rationale for this acquisition is centered on technical synergy and market expansion. By combining Haselmeier’s competence in self-injection devices with Sulzer’s existing expertise in precision injection molding and liquid mixing, the group intends to accelerate the development of innovative and differentiated medical devices. This move allows Sulzer to pivot its APS division toward the high-growth pharmaceutical market, particularly in indications requiring frequent subcutaneous injections. The integration is expected to yield substantial cost synergies through the insourcing of manufacturing processes and the utilization of Sulzer’s global industrial infrastructure.

HASELMEIER, which reported an EBITDA margin of in 2019, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in the 20th century, Haselmeier is a leading Swiss-German developer and manufacturer of innovative drug delivery systems, specializing in subcutaneous self-injection devices. The company operates a high-value business model centered on proprietary intellectual property (IP), providing customized solutions such as injection pens for fast-growing medical indications including diabetes, reproductive health, growth disorders, and osteoporosis. Its value proposition lies in its end-to-end service offering, covering the entire product lifecycle from initial design, prototyping, and engineering to industrial-scale production in modern manufacturing facilities. Haselmeier’s strategy emphasizes being a reliable development partner for pharmaceutical companies, offering additional services such as lifecycle management, pharmaceutical packaging, and regulatory support. By focusing on patented platform technologies for injection devices, the company ensures the safe and precise self-administration of liquid drugs, catering to the increasing global demand for home-based healthcare and patient-centric delivery solutions.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2019

2018

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
01/2021	ARDIAN / BNP PARIBAS DEVELOPPEMENT	PROTEOR	FRANCE	Implants & Prosthetics
11/2020	NOVALPINA CAPITAL	LABORATOIRE X.O	FRANCE	Generics / Labs
10/2020	ARDIAN	H2 PHARMA	FRANCE	CDMO
09/2020	EQT PARTNERS	SCHÜLKE	GERMANY	Medical Consumables
09/2020	PATRICIA INDUSTRIES	ADVANCED INSTRUMENTS	UNITED STATES	Diagnostic Equipment
09/2020	PERMIRA	NEURAXPHARM	GERMANY	Generics / Labs
06/2020	AVISTA CAPITAL PARTNERS	VISION HEALTHCARE	BELGIUM	Nutrition & Dietary Supplements
04/2020	ROYAL DSM	GLYCOM	DENMARK	Nutrition & Dietary Supplements
04/2020	WARBURG PINCUS	POLYPLUS	FRANCE	R&D Biotech
04/2020	AMERICAN SECURITIES	PARAGON MEDICAL	UNITED STATES	Medical Devices

REFERENCES

Valuation range: EV 100M - 350M EUR

Revenue range: 25M - 50M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of HASELMEIER by SULZER are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.